Cerivastatin in primary hyperlipidemia: A multicenter analysis of efficacy and safety

American Journal of Cardiology

Volumn 82, Issue 4 B, 1998, Pages 40J-46J

  Stein, Evan ^a  

^a Pharmaceutical Product Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN;

ADULT; AGED; ARTHRALGIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPOLIPEMIA; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MYALGIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 0032572779     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00436-6     Document Type: Conference Paper

References (25)

1. Blum C.B., Levy R.I. Current therapy for hypercholesterolemia. JAMA. 261:1989;3582-3587.
2. Angerbauer R., Bischoff H., Steinke W., Ritter W. BAY w 6228 hypolipidemic HMG-CoA reductase inhibitor . Drugs Fut. 19:1994;537-541.
3. Bischoff H., Angerbauer R., Bender J., Bischoff E., Faggiotto A., Petzinna D., Pfitzner J., Porter M.C., Schmidt D., Thomas G. Cerivastatin pharmacology of a novel synthetic and high active HMG-CoA reductase inhibitor . Atherosclerosis. 135:1997;119-130.
4. Frey R., Mazzu A.L., Ritter W., Heller A.H., Kuhlmann J. Safety and tolerability of rivastatin, a novel HMG-CoA reductase inhibitor, in phase-I single dose studies. (Abstr.) Naunyn Schmiedebergs Arch Pharmacol. 347:1993;R30.
5. Mazzu A.L., Lettieri J., Kaiser L., Frey R., Heller A.H. Ascending multiple dose safety, tolerability and pharmacodynamics of rivastatin in humans. (Abstr. No.PIII-95) Clin Pharmacol Ther. 53:1993;230.
6. Mück W., Ritter W., Dietrich H., Frey R., Kuhlmann J. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther. 35:1997;621-624.
7. Mück W., Ritter W., Frey R., Wetzelsberger N., Lucker P.W., Kulhmann J. Influence of cholestyramine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther. 35:1997;250-254.
8. Lettieri J., Krol G., Mazzu A.L., Fiebach M., Heller A.H. Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin. Atherosclerosis. 130:(suppl):1997;29-109.
9. Schall R., Müller F.O., Hundt H.K.L., Ritter W., Duursema L., Groenewoud G., Middle M.V. No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin. J Clin Pharmacol. 35:1995;306-313.
10. Mück W., Ochmann K., Unger S., Kuhlmann J. Influence of erythromycin pre-and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Clin Pharmacol Ther. 53:1998;469-473.
11. Lettieri J., Krol G., Mazzu A.L., Shah A., Falk R., Beck C. Effect of age and gender on the steady-state pharmacokinetics of rivastatin. (Abstr. No. PPDM 8159) Pharm Res. 10:(suppl):1993;S338.
12. Vormfelde S, Freudenthaler S, Mück W, Heyen P, Schmage N, Kuhlmann J, Gundert-Remy U, Gleiter CH. Pharmacokinetics of cerivastatin in subjects with normal and impaired renal function. Br J Clin Pharmacol 1997; in press.
13. Shepherd J., Cobbe S.M., Ford C.G., Isles A.R., Lorimer P.W., MacFarlane J.H., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
14. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
15. Pedersen T.R. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
16. Bradford R.H., Shear C.L., Chremos A.N., Dujovne C., Downton M., Franklin F.A., Gould A.L., Hesney M., Higgins J., Hurley D.P., Langendörfer A., Nash D.T., Pool J.L., Schnaper H. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolaemia. Arch Intern Med. 151:1991;43-49.
17. Peters T.K., Mehra M., Muratti E.N. Efficacy and safety of fluvastatin in hypertensive patients. An analysis of a clinical trial database. Am J Hypertens. 6:(suppl):1993;340S-345S.
18. Hunninghake D.B., Mellies M.J., Goldberg A.C., Kuo P.T., Kostis J.B., Schrott H.G., Insull W., Pan H.Y. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. Atherosclerosis. 85:1990;81-94.
19. McDowell I.F.W., Smye M., Trinick T., Shortt J.A., Archibald M.P., Trimble E.R., Nicholls D.P. Simvastatin in severe hypercholesterolaemia a placebo-controlled trial . Br J Clin Pharmacol. 31:1991;340-343.
20. Stein E.A., Isaacsohn J., Stoltz R., Mazzu A.L., Liu M.C., Lane C., Heller A.H. Efficacy and safety of 0.8 mg dosage of cerivastatin, a novel HMG-CoA reductase inhibitor. (Abstr.) J Am Coll Cardiol. 31:1998;281A.
21. Hsu I., Spinler S.A., Johnson N.E. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother. 29:1995;743-759.
22. Bakker-Arkema R.G. Efficacy and safety of a new HMG-CoA reductase inhibitor atorvastatin, in patients with hypertriglyceridemia. JAMA. 275:1996;128-133.
23. Stein E.A., Lane M., Laskarzewski P.L. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 81:(suppl):1998;66B-69B.
24. Blum C.B. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am J Cardiol. 73:(suppl):1994;3D-11D.
25. Transon C., Leemann T., Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 50:1996;209-215.